Lipid molecules can be used for cancer growth

cancer cells
Credit: Min Yu (Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC),USC Norris Comprehensive Cancer Center

When the blood supply is low, cancer cells can use lipid molecules as fuel instead of blood glucose. This has been shown in animal tumour models by researchers at Karolinska Institutet, Sweden, in a study published in Cell Metabolism. The mechanism may explain why tumours often develop resistance to cancer drugs that inhibit the formation of blood vessels.

Tumour growth and spread rely on angiogenesis, a process of growing new that supply the cancer with nutrients and hormones, including glucose (sugar). Treatment with antiangiogenic drugs reduces the number of vessels in the tumour as well as the blood glucose supply. Many such drugs have been developed and are now used in human patients for treating various cancer types. However, the clinical benefits of antiangiogenic drugs in cancer patients are generally low and the cancers treated often develop a resistance to drugs, especially cancer types that grow close to fat tissues such as breast cancer, pancreatic cancer, liver cancer and prostate cancers.

In collaboration with Japanese and Chinese scientists, a research group at Karolinska Institutet in Sweden has discovered a new mechanism by which cancers can evade antiangiogenic treatment and become resistant.

The reduction of tumour blood vessels results in low oxygenation in tumour tissues—a process called hypoxia. In the current study, the researchers show that hypoxia acts as a trigger to tell fat cells surrounding or within tumour tissues to break down the stored excessive lipid energy molecules. These lipid energy molecules can when the blood supply is low be used for cancer tissue expansion.

"Based on this mechanism, we propose that a combination therapy consisting of antiangiogenic drugs and drugs blocking lipid energy pathways would be more effective for treating cancers. In animal models, we have validated this very important concept, showing that combination therapy is superior to monotherapy," says Yihai Cao, Professor at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet, who led the study.

Professor Cao's group now plans to work with companies and clinical oncologists to explore whether such a new combination therapy would improve the quality of life and lifespan in human patients.

More information: "Cancer lipid metabolism confers antiangiogenic drug resistance"Cell Metabolism (2018).

Journal information: Cell Metabolism
Citation: Lipid molecules can be used for cancer growth (2018, June 1) retrieved 28 March 2024 from https://medicalxpress.com/news/2018-06-lipid-molecules-cancer-growth.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

CD93 protein suggests new strategy to inhibit cancer

187 shares

Feedback to editors